Norgine has announced that Swissmedic has approved the registration of IFINWIL (eflornithine) as a monotherapy for treating ...

The Swiss Agency for Therapeutic Products (Swissmedic) has approved Novartis’ Coartem (artemether-lumefantrine) Baby, ...

Swissmedic has introduced a fast-track review process for clinical trial applications, aiming to speed up access to ...

Novartis and a Swiss nonprofit have made history, scoring the world’s first approval for a medicine to treat babies who are ...

Swissmedic approves IFINWIL® (eflornithine) for children diagnosed with high-risk neuroblastoma (HRNB) News provided by. Norgine Jul 08, 2025, 8:01 AM ET IFINWIL ® ...

The newly approved medication, Coartem Baby, is a combination of two antimalarials. It is a lower dose version of a tablet ...

The medicine, called Coartem Baby (also known as Riamet Baby), was approved by Switzerland’s health agency, Swissmedic.

Swissmedic approves Novartis’ Coartem Baby to treat malaria in newborns and young infants: Basel Thursday, July 10, 2025, 11:00 Hrs [IST] Novartis announced Coartem (artemether- ...

Switzerland’s health regulator Swissmedic granted marketing authorisation on Tuesday for Novartis Riamet Baby, also known as ...

Swissmedic approves Norgine’s Ifinwil for children diagnosed with high-risk neuroblastoma: Uxbridge, UK Thursday, July 10, 2025, 17:00 Hrs [IST] Norgine, a leading European spec ...

The Swiss Agency for Therapeutic Products (Swissmedic) has approved Novartis’ Coartem (artemether-lumefantrine) Baby, described as the first malaria medicine for newborns and young infants ...

WEDNESDAY, July 9, 2025 (HealthDay News) — A new malaria treatment has been approved for newborns and infants under 11 pounds, filling a major gap in care for some of the most vulnerable children.